Leader in liquid biopsy
Sysmex Inostics, a pioneering leader in liquid biopsy, offers comprehensive NGS testing services for clinical trials, enhancing oncology drug development and patient outcomes.
Our Mission
To uncover actionable molecular insights, with a seamless, end-to-end solutions for your clinical trials, without compromise or complexity.
Our Values
Anshin is a Japanese word at the core of the Sysmex corporate philosophy which means “peace of mind”. It is the singular guiding principle by which we do our work at Sysmex Inostics.
At Sysmex-Inostics, anshin stands for a state in which:
- Customers have no concerns about the safety and quality of our products and services.
- Stakeholders can trust, be confident and reassured in our relationship, transactions, interaction, and all other matters.
- Individuals in society can be in a calm state of mind with little or no anxiety about their own health, lives, or other matters. We aim to ensure anshin with unmatched quality, advanced technology, mindful support, and actions that reflect the needs of our customers.
We constantly seek to better understand what our customers require so that we may generate new and more satisfactory solutions.
Our Pledge
The measure of our success will be in the response our customers have to our business approach. We commit to unwavering excellence in the delivery of solutions, leading to improved outcomes of patients with cancer.
Our Culture
We care about every molecule and every detail, and we have a passion for discovery. We are intelligent and optimistic, and focus on lighting a way forward to support the future of healthcare.
Our Experience
- We are leaders in the liquid biopsy revolution and have been a CLIA Certified lab specializing in liquid biopsy since 2011
- Our global reach through our parent company Sysmex Corporation and our strategic partnership with QIAGEN® allow us to provide robust CDx development and therapy commercialization capabilities
- Our industry expertise has advanced several oncology therapies currently on the market
- We have access to a myriad of powerful somatic variant detection solutions and are able to customize assays to fit your clinical study needs
Our History
A lab like none other. A history of exploration and innovation.
BEAMing (OncoBEAM™) is developed as the first dPCR ctDNA technology (Liquid Biopsy).1
We formed Inostics to be the first Liquid Biopsy provider.
Plasma-Safe-SeqS (PSS) is developed as the first UMI-based NGS Liquid Biopsy technology.2
Our CLIA lab is established to offer the first clinical Liquid Biopsy services for patients in 2013.
Sysmex acquires Inostics to add IVD expertise and global market access capabilities.
PSS is shown to have equivalent sensitivity to OncoBEAM.3
BC-SEQ and RAS-RAF-SEQ become Sysmex Inostics’ first CLIA validated PSS testing services.
AML-MRD-SEQ shows promise for recurrence monitoring.4
HPV-SEQ and AML-MRD-SEQ are added to our Baltimore CLIA Lab’s test menu.
QIAGEN® becomes our CDx partner.
HPV-SEQ is proven to detect HPV 16 & 18 in the blood of patients5
NSCLC-SEQ has equivalent sensitivity to OncoBEAM.6
HNSCC-SEQ and AML-SEQ are added to our Test Menu.
HPV-SEQ is used to de-escalate treatment of HPV-driven cancer patients.7
References:
- Dressman 2003 PNAS
- Kinde 2011 PNAS
- Rugo AACR 2019
- Sloane ASH 2020
- Sloane ASH 2020
- Sloane AACR 2021
- Rosenberg BMS 2022